Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adios To Alcon In April As Novartis Confirms Spin-Off Date

Executive Summary

With the eye-care business set for its own stock exchange listings next month and the future of Sandoz the subject of much discussion, Novartis' plan to be a pure play pharma firm moves ever closer.

Advertisement

Related Content

Lumify Ad Launches As Bausch Spends More Behind OTC Eye Care Brands
Novartis Delighted With Xiidra Deal Despite Eye-Watering Price
Novartis CEO Issues Staunch Defense of Zolgensma As Sales Soar
How Roche Won The Bidding Battle For Spark
Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza
Novartis' Siponimod Heads Towards Regulators As Experts Question Its Effects

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124954

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel